atai Life Sciences Increases its Ownership Position in COMPASS Pathways Post published:November 29, 2021 Post category:Press Release
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update Post published:November 15, 2021 Post category:Press Release
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia Post published:November 1, 2021 Post category:Press Release
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change Post published:October 19, 2021 Post category:Press Release
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD) Post published:October 11, 2021 Post category:Press Release
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Post published:September 21, 2021 Post category:Press Release
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data Post published:September 15, 2021 Post category:Press Release
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Post published:September 14, 2021 Post category:Press Release
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression Post published:September 9, 2021 Post category:Press Release
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update Post published:August 16, 2021 Post category:Press Release